

A new therapy for global prevention of haemolytic disease of the newborn (HDFN)

The Problem

- The current blood-derived anti-RhD standard-of-care (SoC) does not meet the global demand
- As recently as 2025, FDA has reported shortages
- Globally 50% of women cannot access the current SoC resulting in foetal death and disability
- The current SoC is unsustainable due to its dependency on blood donations


The Solution

- We are developing a standardised, scalable and reliable recombinant anti-RhD antibody
- Our solution will guarantee the quality and supply of anti-RhD prophylaxis globally

Our Program

- Collaboration with Australian Red Cross Lifeblood (ARCL)
- Progress: Identified a recombinant lead antibody, benchmarked data with commercial product and assessed *in vitro* functional assays and epitope mapping of RhD variants

Seeking **partnerships and funding** for preclinical studies and antibody development
(manufacturing, regulatory guidance, clinical trials)



Our Team

Prof. Ian Wicks, Antibody-based therapies/Clinician
Dr. Behnaz Heydarchi, Antibody-based therapies
Prof. David Irving, Australian Red Cross Lifeblood

Onisha Patel, PhD, Business Development,
patel.o@wehi.edu.au